retatrutide phase 2 trial type 2 diabetes results 2024 This data from 3 clinical trials for was announced yesterday at @amdiabetesassn #ADA2026 ✓ We are fortunate to be living in a time where there multiple medications which safely reduce Retatrutide produces up to 30.3%

A historical cohort investigation of 29 patients with comorbid mood disorder and obesity noted that liraglutide-induced weight loss over 6 months was not associated with changes in psychiatric symptoms, although less than half of the study population completed the study period 180

Mounjaro (tirzepatide) Mounjaro ( tirzepatide ) is another medication with a dual-action mechanism , targeting GLP-1 and GIP receptors but, unlike retatrutide, it doesnt target glucagon receptors

It actively increases how many calories your body burns, even at rest

contact your GP for persistent nausea, mood changes, libido disturbance, or hormonal symptoms

Retatrutide: Side effects and warnings Clinical trials show that 6 to 16% of participants stopped taking retatrutide due to side effects, mostly gastrointestinal symptoms that tend to improve as your body adjusts

The studys results provide insights into some known and previously unrecognized benefits and risks of GLP-1RA that may be useful to inform clinical care and guide research agendas. Potential Downsides to GLP-1s Al-Aly emphasizes that his study also highlighted potential downsides to the medications, including an increased risk of gastrointestinal problems such as nausea, vomiting, diarrhea, and in rare cases paralysis of the stomach